[Drug-induced heart failure].
Asakura
Masanori
M
Department of Research and Development of Clincal Research, National Cardiovascular Center.
Kitakaze
Masafumi
M
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002121:Calcium Channel Blockers / Q000009:adverse effects; D003520:Cyclophosphamide / Q000009:adverse effects; D004317:Doxorubicin / Q000009:adverse effects; D005938:Glucocorticoids / Q000009:adverse effects; D006333:Heart Failure / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D006801:Humans; D000068878:Trastuzumab
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D002121:Calcium Channel Blockers; D005938:Glucocorticoids; D004317:Doxorubicin; D003520:Cyclophosphamide; D000068878:Trastuzumab